Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

FDA Public Meeting On Rx Risk, Benefit Communication Slated For December

Executive Summary

FDA will hold a public hearing on ways to better communicate information about drug risks and benefits, FDA Drug Safety Oversight Board Executive Director Susan Cummins said at the PDA/FDA Joint Regulatory Conference in Washington, D.C. on Sept. 13
Advertisement

Related Content

FDA Drug Risk Communication Should Include Drug Benefit Info, PhRMA Says
FDA Drug Risk Communication Should Include Drug Benefit Info, PhRMA Says
FDA’s Drug Safety Oversight Board Adds Staff To Manage Operations
FDA’s Drug Safety Oversight Board Adds Staff To Manage Operations
One Year After Vioxx, Pendulum May Be Swinging Back To Efficacy At FDA
One Year After Vioxx, Pendulum May Be Swinging Back To Efficacy At FDA
Rx risk communication meeting
FDA Unveils Rx Safety Board, Website; Postmarket Surveillance Overhaul Next
IoM Drug Safety Study May Buy Time For FDA; Report Will Play In PDUFA IV
IoM Drug Safety Study May Buy Time For FDA; Report Will Play In PDUFA IV

Topics

Advertisement
UsernamePublicRestriction

Register

PS046325

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel